急性ST段抬高型心肌梗死药物治疗与药师角色(第一部分)
该综述从临床药师视角梳理STEMI患者从就诊至血运重建期间的关键药物治疗,包括血运重建前支持治疗、经皮冠状动脉介入和/或纤溶治疗中的抗血栓药物及其他围术期用药,指出药师在该高风险时段角色定位不连续且文献支持有限,呼吁进一步研究药师对患者和机构结局的影响。
要点
- STEMI急性期涵盖多阶段复杂药物治疗决策,药师介入机会丰富但服务不连续。
- 血运重建前后涉及多种抗血栓药物及围术期用药,是药师优化治疗的关键节点。
- 现有文献对药师在STEMI急性管理中的作用描述与支持有限,需进一步研究。
核心结论
- STEMI患者快速经历多个治疗阶段并接受大量抗血栓及支持药物,为药师提供重要药物治疗决策角色。
研究设计与样本
- 综述文献,总结STEMI初始阶段关键药物治疗模式与考量,从临床药师视角汇总重要实践指南与临床资源。
主要发现
- 尽管在急诊、心脏监护和重症监护环境中已确立价值,但目前很少有公开发表的文献描述或支持临床药师在STEMI急性管理中的角色。
- 从入院至血运重建和稳定的高风险期涉及复杂药物治疗决策点、大量操作性用药需求和多重质量监管。
- 临床药学服务对该时间段的覆盖不一致,可能在急诊评估后停止,直至导管术后心脏病房入院时恢复。
临床怎么用
- 建议药师关注血运重建前支持治疗、经皮冠状动脉介入和/或纤溶治疗中的抗血栓药物及其他围术期用药的管理。
- 可参考文中汇总的实践指南与临床资源,明确响应药师的职责与责任。
局限性
- 目前很少有公开发表的文献描述或支持临床药师在STEMI急性管理中的角色。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Key pharmacotherapeutic modalities and considerations for the patient with ST-elevation myocardial infarction (STEMI) across the critical initial phases of care are reviewed. SUMMARY: Despite established value in the emergency department (ED), cardiac care, and intensive care settings, there is currently little published literature describing or supporting clinical pharmacist roles in the acute management of STEMI. The high-risk period from hospital presentation through revascularization and stabilization involves complex pharmacotherapeutic decision points, many operational medication needs, and multiple layers of quality oversight. While rife with opportunities for pharmacists to optimize care, this timeframe appears inconsistently targeted by clinical pharmacy services, which may halt after ED evaluation and then resume upon postcatheterization cardiac unit admission. Herein we review the key pharmacotherapeutic modalities and considerations for the patient with STEMI across the critical initial phases of care. These include supportive therapies prior to revascularization, the host of antithrombotics involved in revascularization by percutaneous coronary intervention and/or fibrinolysis, and other periprocedural medications. Important practice guidelines and clinical resources are summarized from the clinical pharmacist perspective, and roles and responsibilities of the responding pharmacist are suggested. A companion article will extend the review to periprocedural adverse event management, key early decision-making regarding long-term risk reduction, and pharmacist involvement in institutional quality improvement efforts. We aim to support inpatient pharmacy departments in advancing clinical services for this critical patient population, and we call for further research delineating pharmacist impact on patient and institutional STEMI outcomes. CONCLUSION: Patients presenting with STEMI rapidly traverse multiple phases of care and receive a host of antithrombotic and supportive medications during acute management, presenting many important pharmacotherapeutic decision points and roles for pharmacists.
引用
- Hyland SJ, Eaton RE, Max ME, et al. Pharmacotherapy of acute ST-elevation myocardial infarction and the pharmacist's role, part 1: Patient presentation through revascularization. Am J Health Syst Pharm. 2025. PMID: 39450757. doi:10.1093/ajhp/zxae303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。